HomeCompareBBI vs SBUX

BBI vs SBUX: Dividend Comparison 2026

BBI yields 85.11% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBI wins by $1.91M in total portfolio value
10 years
BBI
BBI
● Live price
85.11%
Share price
$2.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.08M
Annual income
$627,483.66
Full BBI calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BBI vs SBUX

📍 BBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBISBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBI + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBI pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBI
Annual income on $10K today (after 15% tax)
$7,234.04/yr
After 10yr DRIP, annual income (after tax)
$533,361.11/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, BBI beats the other by $472,895.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBI + SBUX for your $10,000?

BBI: 50%SBUX: 50%
100% SBUX50/50100% BBI
Portfolio after 10yr
$1.12M
Annual income
$349,310.06/yr
Blended yield
31.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BBI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-7.2
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBI buys
0
SBUX buys
0
No recent congressional trades found for BBI or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBISBUX
Forward yield85.11%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$2.08M$167.0K
Annual income after 10y$627,483.66$71,136.45
Total dividends collected$1.82M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: BBI vs SBUX ($10,000, DRIP)

YearBBI PortfolioBBI Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$19,211$8,510.64$11,121$420.68+$8.1KBBI
2$35,835$15,279.89$12,548$648.40+$23.3KBBI
3$64,982$26,638.22$14,440$1,013.98+$50.5KBBI
4$114,675$45,144.37$17,068$1,617.30+$97.6KBBI
5$197,158$74,455.37$20,912$2,649.52+$176.2KBBI
6$330,593$119,634.65$26,875$4,499.29+$303.7KBBI
7$541,214$187,479.44$36,771$8,014.12+$504.4KBBI
8$865,943$286,843.50$54,542$15,197.11+$811.4KBBI
9$1,355,484$428,924.80$89,602$31,242.49+$1.27MBBI
10$2,077,851$627,483.66$167,011$71,136.45+$1.91MBBI

BBI vs SBUX: Complete Analysis 2026

BBIStock

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Full BBI Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BBI vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBI vs SCHDBBI vs JEPIBBI vs OBBI vs KOBBI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.